<h1>Foreign sequencing company and South Korean biotech sign MoU to launch multi-omics lab, raise IP, data and regulatory issues</h1> A foreign sequencing technology company and a South Korean biotechnology firm have executed a memorandum of understanding to establish a collaborative laboratory initiative in South Korea providing end-to-end multi-omics sequencing platforms and services. The agreement contemplates technology deployment, joint research in multi-omics and precision medicine, clinical translation activities, and AI-driven data analysis, positioning the lab as a regional genomics hub. Legal considerations likely include intellectual property ownership and licensing of platform technologies, data governance and cross-border data transfer compliance, regulatory approvals for clinical applications, liability allocation, and terms governing commercialization and ongoing collaboration.